In March 2025, SFA Therapeutics announced that two head-to-head preclinical studies of its oral psoriasis therapy candidate, ...

The skin on different areas of the body requires different regimens. Here’s how dermatologists recommend treating it on your ...

Adults with worse cardiovascular-kidney-metabolic health are at an increased risk of developing psoriasis, especially in those with high genetic risk.

Psoriasis has been linked to other chronic health complications. Here’s how the condition increases the risk of heart disease ...

Patients with psoriasis face higher risk for several different types of cancer, according to the results of an international study.

Personalized dosing strategies may be necessary for biologic therapies, especially fixed-dose options like ustekinumab, due ...

New longitudinal research reveals that severe stress caused by changes in family structure like divorce or separation ...

The use of dupilumab for the treatment of atopic dermatitis was associated with an increased risk of psoriasis compared with other systemic agents. The association between dupilumab and psoriasis was ...

Disease modifying mechanism of action: short treatment course results in significant and durable clinical response in psoriasis patients si-544 ...

YUFLYMA® (adalimumab-aaty), and its unbranded version, are now approved for two additional pediatric indications - adolescent hidradenitis suppurativa (HS) and pediatric uveitis (UV), in the ...